One of the difficulties in the use of reprogrammed cells (iPS cells) is the low efficiency. Now, a technical step has been taken to substantially increase this. Using it, Australian researchers, combining it with the genome editing technique CRISPR-Cas9, have been able to generate normal cells from the cells of two patients, one with retinal cell degeneration and the other a child with severe immune deficiency, which opens the door to its possible clinical use.
La entrada Improved efficacy in the generation of iPS cells for clinical use aparece primero en Observatorio de Bioética, UCV.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.